Ionis Pharmaceuticals INC Form 4 insider transactions

Ionis Pharmaceuticals' EVP, Chief Development Officer, Richard S. Geary, exercised stock options and subsequently sold shares totaling 34,639 shares in early November 2025.

Ionis Pharmaceuticals' EVP, Chief Development Officer, Richard S. Geary, filed an amended Form 4 to correct previously reported stock option exercises and sales.

Ionis Pharmaceuticals Director Joseph H. Wender sold 27,900 shares of common stock in late October 2025 under a pre-arranged 10b5-1 trading plan.

Ionis Pharmaceuticals Director Joseph Loscalzo exercised stock options and subsequently sold 16,000 shares of common stock under a pre-arranged trading plan.

Ionis Pharmaceuticals' EVP, Chief Development Officer, Richard S. Geary, sold a net of 20,000 shares of common stock through pre-arranged trading plans.

Ionis EVP Research Eric Swayze acquired shares from RSU vesting; indirect shares by son sold for tax.

Ionis Pharmaceuticals Director B. Lynne Parshall sold 5,000 shares of common stock for approximately $71.74 per share under a pre-arranged trading plan.

Shannon L. Devers, EVP, Chief Human Resources Officer at Ionis Pharmaceuticals, reported exercising stock options and selling shares, including a tax-related sale.

Ionis Pharmaceuticals EVP Brian Birchler exercised stock options and subsequently sold shares totaling over $1.7 million under a pre-arranged trading plan.

Ionis Pharmaceuticals EVP of Research, Eric Swayze, sold 6,849 shares of common stock for a weighted average price of $69.02 per share under a pre-arranged 10b5-1 trading plan.

Ionis Pharmaceuticals' EVP, CLO & General Counsel, Patrick R. O'Neil, exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged 10b5-1 trading plan.

Ionis Pharmaceuticals CEO Brett P. Monia sold 437 shares of common stock for $69.2637 per share on October 6, 2025, under a pre-arranged 10b5-1 trading plan.

Joseph Baroldi, EVP and Chief Business Officer of Ionis Pharmaceuticals, sold 1,625 shares of common stock for $69.3693 per share on October 6, 2025, under a pre-arranged 10b5-1 trading plan.

Ionis Pharmaceuticals Director Joseph H. Wender sold 16,800 shares of common stock for approximately $1.1 million on October 1, 2025, under a pre-arranged trading plan.

Ionis Pharmaceuticals EVP of Research, Eric Swayze, sold common stock totaling 27,114 shares in pre-planned transactions.

Patrick R. O'Neil, EVP CLO & General Counsel of Ionis Pharmaceuticals, exercised stock options and sold common stock totaling 64,664 shares on October 2, 2025, under a pre-arranged trading plan.

Ionis Pharmaceuticals' EVP, Chief Business Officer Joseph Baroldi, exercised stock options and subsequently sold 15,000 shares of common stock under a pre-arranged 10b5-1 trading plan.

Ionis Pharmaceuticals' EVP, CLO & General Counsel, Patrick R. O'Neil, sold shares totaling over $1.6 million in late September 2025, following the exercise of stock options under a pre-arranged 10b5-1 trading plan.

Richard S. Geary, EVP and Chief Development Officer at Ionis Pharmaceuticals, sold 57,900 shares of common stock for $65.24 per share after exercising stock options.

Ionis Pharmaceuticals' EVP, Finance & CFO, Elizabeth L. Hougen, exercised stock options and subsequently sold 49,800 shares under a pre-arranged 10b5-1 trading plan.

Patrick R. O'Neil, EVP CLO & General Counsel at Ionis Pharmaceuticals, executed a pre-planned sale of 1,700 common shares after exercising stock options.

Ionis Pharmaceuticals' EVP, Chief Business Officer Joseph Baroldi, exercised stock options and subsequently sold 11,950 shares under a pre-arranged 10b5-1 trading plan.

Ionis Pharmaceuticals' EVP, CLO & General Counsel, Patrick R. O'Neil, reported the sale of 21,000 common shares under a pre-arranged Rule 10b5-1 trading plan.

Ionis Pharmaceuticals' EVP, Chief Business Officer Joseph Baroldi, exercised stock options and subsequently sold an equal number of common shares under a pre-arranged plan.

Ionis Pharmaceuticals' Chief Scientific Officer, C. Frank Bennett, sold 6,000 shares of common stock for approximately $59.60 per share as part of a pre-arranged trading plan.

Ionis Pharmaceuticals EVP of Research, Eric Swayze, sold over 11,000 shares of common stock through a pre-arranged trading plan.

Ionis Pharmaceuticals director Joseph H. Wender sold 28,000 shares of common stock in early September 2025 under a pre-arranged 10b5-1 trading plan.

Ionis Pharmaceuticals Director B. Lynne Parshall sold a total of 20,000 shares of common stock in early September 2025 under a pre-arranged trading plan.

Ionis Pharmaceuticals CEO Brett P. Monia executed a series of stock option exercises and subsequent share sales totaling over $12 million on September 3, 2025, under a pre-arranged 10b5-1 trading plan.

Ionis Pharmaceuticals Director Joseph Klein III sold 28,000 shares of common stock for $60.00 per share after exercising stock options, as part of a pre-arranged 10b5-1 trading plan.